US · Healthcare · Biotechnology
EPS came in at -0.59 against a street estimate of -0.48 — a miss of 22.9%.
Analysts rate SpyGlass Pharma, Inc. a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $44.00.
| Fund | Stake |
|---|---|
| RA Capital Management, LLC | 23.98% |
| NEA Management Company, LLC | 22.10% |
| Sands Capital Ventures, LLC | 7.47% |
| Samsara BioCapital, LLC | 6.31% |
| BlackRock Inc | 2.13% |
| T. Rowe Price Associates, Inc. | 2.02% |
| Vestal Point Capital LP | 2.00% |
| JPMorgan Chase & Co | 1.88% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q4 2026 HEADLINE NUMBERS • SpyGlass Pharma completed the acquisition of Advanced Vision Science, Inc. (AVS) on October 1, 2026. • The company paid a purchas | 2026-10-01 |
| Quarterly report · Q2 2026 SPYGLASS PHARMA, INC. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $223.1 million in cash and equivalents as of June 30, 2026 (up from $ | 2026-08-06 |
| Results announced · Q3 2026 SPYGLASS PHARMA Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash, cash equivalents and short-term investments: $234.2 million as of June 30, 2026 • | 2026-08-06 |
| Quarterly report · Q1 2026 SPYGLASS PHARMA, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash Position: $238.9 million in cash and cash equivalents as of March 31, 2026 (up | 2026-05-14 |
| Results announced · Q2 2026 SPYGLASS PHARMA Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash, cash equivalents and short-term investments: $251.0 million as of March 31, 2026 | 2026-05-14 |
| Annual report FY2025 SPYGLASS PHARMA, INC. — FORM 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: SpyGlass Pharma, Inc., traded as SGP on Nasdaq • Shares o | 2026-03-26 |
| Results announced · Q1 2026 SPYGLASS PHARMA - EARNINGS SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • IPO completed February 9, 2026: raised $172.5 million gross proceeds, lis | 2026-03-26 |
| Company announcement · Q1 2026 SPYGLASS PHARMA, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company issued press release on March 9, 2026 announcing positive 12-month clinical trial | 2026-03-09 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for SpyGlass Pharma, Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.